Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

ferring gmbh, wittland 11, kiel, njemačka - triptorelinacetat - prašak i otapalo za suspenziju za injekciju - 3,75 mg - urbroj: 1 napunjena štrcaljka s praškom sadrži 3,75 mg triptorelinacetata (1 ml pripremljene suspenzije sadrži 3,69 mg triptorelinacetata)

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

clinres farmacija d.o.o. - трипторелин - prašak i otapalo za suspenziju za injekciju - 3.75 mg/1 ml - 1 ml suspenzije za injekciju sadrži: 3,75 mg triptorelina (u obliku triptorelin acetata)

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

ferring gmbh, wittland 11, kiel, njemačka - triptorelinacetat - otopina za injekciju u napunjenoj štrcaljki - 0,1 mg/ml - urbroj: jedna napunjena štrcaljka s 1 ml otopine za injekciju sadrži 100 mikrograma triptorelinacetata, što odgovara 95,6 mikrograma slobodne baze triptorelina

Bosna i Hercegovina - hrvatski - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

clinres farmacija d.o.o. - трипторелин - otopina za injekciju - 0.1 mg/1 ml - 1 ml otopine za injekciju sadrži: 0,1 mg triptorelin acetata

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

a&b d.o.o., zagreb - uređaj za automatsko procesuiranje tkiva

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

a&b d.o.o., zagreb - in vitro dijagnostika u patologiji

Europska Unija - hrvatski - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - odbacivanje transplantata - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

pharmascience international limited, lampousas, 1, nicosia, cipar - tikagrelor - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 60 mg tikagrelora

Hrvatska - hrvatski - HALMED (Agencija za lijekove i medicinske proizvode)

pharmascience international limited, lampousas, 1, nicosia, cipar - tikagrelor - filmom obložena tableta - urbroj: jedna filmom obložena tableta sadrži 90 mg tikagrelora

Europska Unija - hrvatski - EMA (European Medicines Agency)

nps pharma holdings limited - paratiroidni hormon (rdna) - osteoporoza, postmenopauzalna - homeostaza kalcija - liječenje osteoporoze u žena u postmenopauzi s visokim rizikom od prijeloma (vidjeti odjeljak 5. značajno smanjenje pojavnosti kralješaka, no ne i fraktura kuka, pokazano je.